The present invention relates to methods of treating tuberculosis, including multidrug resistant varieties and latent tuberculosis. More particularly, the present invention relates to a method of treating tuberculosis in a mammal comprising administering to said mammal in need thereof an effective amount of a compound of formula (T), (S)—N-[[3-[3-fluoro-4-(4-thiomor-pholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, or a pharmaceutically acceptable salt thereof in combination with at least two agents useful in the treatment of tuberculosis. The present invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, (ii) a therapeutically effective amount of at least one agent useful in the treatment of tuberculosis and (iii) one or more pharmaceutically acceptable carriers or vehicles.

The present invention relates to methods of treating tuberculosis, including multidrug resistant varieties and latent tuberculosis. More particularly, the present invention relates to a method of treating tuberculosis in a mammal comprising administering to said mammal in need thereof an effective amount of a compound of formula (T), (S)—N-[[3-[3-fluoro-4-(4-thiomor-pholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, or a pharmaceutically acceptable salt thereof in combination with at least two agents useful in the treatment of tuberculosis. The present invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, (ii) a therapeutically effective amount of at least one agent useful in the treatment of tuberculosis and (iii) one or more pharmaceutically acceptable carriers or vehicles.

The instant invention relates to compounds of formula I

##STR00001## wherein: R is selected from H, Me or Cl, and R′ is selected from: H, NH.sub.2, NHCOCH.sub.3 NHCOCF.sub.3 or NHCOCH.sub.2Cl. The invention further provides a process for obtaining the compounds of formula I and their use.

The present disclosure provides methods of treating ataxia in a subject in need thereof by administering a combination of acetyl-leucine and 4-aminopyridine or a combination of acetyl-leucine and acetazolamide to the subject.

The present disclosure provides methods of treating ataxia in a subject in need thereof by administering a combination of acetyl-leucine and 4-aminopyridine or a combination of acetyl-leucine and acetazolamide to the subject.

The present disclosure provides methods of treating ataxia in a subject in need thereof by administering a combination of acetyl-leucine and 4-aminopyridine or a combination of acetyl-leucine and acetazolamide to the subject.

The present disclosure provides a method of treating a subject having a cancer. The method comprises reducing expression of a Carm 1 gene and/or a Carm 1 effector gene in a cell of the subject, and/or reducing activity of a Carm 1 protein and/or a Carm 1 effector protein in a cell of the subject. The cancer is resistant to immunotherapy and/or checkpoint blockade treatment.

The present disclosure provides a method of treating a subject having a cancer. The method comprises reducing expression of a Carm 1 gene and/or a Carm 1 effector gene in a cell of the subject, and/or reducing activity of a Carm 1 protein and/or a Carm 1 effector protein in a cell of the subject. The cancer is resistant to immunotherapy and/or checkpoint blockade treatment.

The invention relates to aqueous suspension pharmaceutical compositions of poorly water soluble drugs, wherein said drugs are selected from compounds of formula (I) (Formula (I)), wherein R.sup.1-R.sup.9 are defined herein; processes for preparing these compositions and their use in medicine, especially their use in the treatment of ocular diseases. ##STR00001##

The invention relates to aqueous suspension pharmaceutical compositions of poorly water soluble drugs, wherein said drugs are selected from compounds of formula (I) (Formula (I)), wherein R.sup.1-R.sup.9 are defined herein; processes for preparing these compositions and their use in medicine, especially their use in the treatment of ocular diseases. ##STR00001##